Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma

Nicole L. Michmerhuizen, Megan L. Ludwig, Andrew C. Birkeland, Sai Nimmagadda, Jingyi Zhai, Jiayu Wang, Brittany M. Jewell, Dylan Genouw, Lindsay Remer, Daniel Kim, Susan K. Foltin, Apurva Bhangale, Aditi Kulkarni, Carol R. Bradford, Paul L. Swiecicki, Thomas E. Carey, Hui Jiang, J. Chad Brenner

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) is a debilitating disease with poor survival. Although epidermal growth factor receptor (EGFR)-targeting antibody cetuximab improves survival in some settings, responses are limited suggesting that alternative approaches are needed. Methods: We performed a high throughput drug screen to identify EGFR inhibitor-based synergistic combinations of clinically advanced inhibitors in models resistant to EGFR inhibitor monotherapies, and then performed downstream validation experiments on prioritized synergistic combinations. Results: From our screen, we re-discovered known synergistic EGFR inhibitor combinations with FGFR or IGF-1R inhibitors that were broadly effective and also discovered novel synergistic combinations with XIAP inhibitor and DNMT inhibitors that were effective in only a subset of models. Conclusions: Conceptually, our data identify novel synergistic combinations that warrant evaluation in future studies, and suggest that some combinations, although highly synergistic, will require parallel companion diagnostic development to be effectively advanced in patients.

Original languageEnglish (US)
JournalHead and Neck
DOIs
StateAccepted/In press - 2022
Externally publishedYes

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this